Cargando…

Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy

OBJECTIVE: To evaluate the predictive value of intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) in the quantitative assessment of conventional chemotherapy-activated immune responses in mouse tumor models and clinics. METHODS: A total of 19 subcutaneous tumor-bearing mice were ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Junjiao, Yu, Xin, Yin, Peidi, Du, Bin, Cai, Xiangran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136146/
https://www.ncbi.nlm.nih.gov/pubmed/35646652
http://dx.doi.org/10.3389/fonc.2022.796936
_version_ 1784714113384972288
author Hu, Junjiao
Yu, Xin
Yin, Peidi
Du, Bin
Cai, Xiangran
author_facet Hu, Junjiao
Yu, Xin
Yin, Peidi
Du, Bin
Cai, Xiangran
author_sort Hu, Junjiao
collection PubMed
description OBJECTIVE: To evaluate the predictive value of intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) in the quantitative assessment of conventional chemotherapy-activated immune responses in mouse tumor models and clinics. METHODS: A total of 19 subcutaneous tumor-bearing mice were randomly divided into treated and control groups. Both groups had orderly IVIM DWI examinations before and on days 6 and 12 after the administration of cyclophosphamide (CPA) or saline. Pathologic examinations were performed, including HE staining and immunohistochemistry (IHC). The expressions of immune-related genes in the tumor were measured by qPCR. In addition, six patients with breast cancer requiring neoadjuvant chemotherapy (NACT) also underwent functional MRI examinations and IHC to determine potential antitumor immune response. RESULTS: At the end of the study, the CPA treatment group showed the lowest tumor volume compared to the control group. For pathological examinations, the CPA treatment group showed a lower percentage of CD31 staining (P < 0.01) and Ki-67 staining (P<0.01), and a higher percentage of TUNEL staining (P < 0.01). The tumoral pseudodiffusion coefficient (D*) value showed a positive correlation with the CD31-positive staining rate (r = 0.729, P < 0.0001). The diffusion related parameters (D) value was positively correlated with TUNEL (r = 0.858, P < 0.0001) and negatively correlated with Ki-67 (r = -0.904, P < 0.0001). Moreover, a strong induction of the expression of the immune responses in the CPA treatment group was observed on day 12. D values showed a positive correlation with the Ifnb1-, CD8a-, Mx1-, Cxcl10- (r = 0.868, 0.864, 0.874, and 0.885, respectively, P < 0.0001 for all). Additionally, the functional MRI parameters and IHC results in patients with breast cancer after NACT also showed a close correlation between D value and CD8a (r = 0.631, P = 0.028). CONCLUSIONS: The treatment response induced by immunogenic chemotherapy could be effectively evaluated using IVIM-DWI. The D values could be potential, sensitive imaging marker for identifying the antitumor immune response initiated by immunogenic chemotherapy.
format Online
Article
Text
id pubmed-9136146
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91361462022-05-28 Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy Hu, Junjiao Yu, Xin Yin, Peidi Du, Bin Cai, Xiangran Front Oncol Oncology OBJECTIVE: To evaluate the predictive value of intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) in the quantitative assessment of conventional chemotherapy-activated immune responses in mouse tumor models and clinics. METHODS: A total of 19 subcutaneous tumor-bearing mice were randomly divided into treated and control groups. Both groups had orderly IVIM DWI examinations before and on days 6 and 12 after the administration of cyclophosphamide (CPA) or saline. Pathologic examinations were performed, including HE staining and immunohistochemistry (IHC). The expressions of immune-related genes in the tumor were measured by qPCR. In addition, six patients with breast cancer requiring neoadjuvant chemotherapy (NACT) also underwent functional MRI examinations and IHC to determine potential antitumor immune response. RESULTS: At the end of the study, the CPA treatment group showed the lowest tumor volume compared to the control group. For pathological examinations, the CPA treatment group showed a lower percentage of CD31 staining (P < 0.01) and Ki-67 staining (P<0.01), and a higher percentage of TUNEL staining (P < 0.01). The tumoral pseudodiffusion coefficient (D*) value showed a positive correlation with the CD31-positive staining rate (r = 0.729, P < 0.0001). The diffusion related parameters (D) value was positively correlated with TUNEL (r = 0.858, P < 0.0001) and negatively correlated with Ki-67 (r = -0.904, P < 0.0001). Moreover, a strong induction of the expression of the immune responses in the CPA treatment group was observed on day 12. D values showed a positive correlation with the Ifnb1-, CD8a-, Mx1-, Cxcl10- (r = 0.868, 0.864, 0.874, and 0.885, respectively, P < 0.0001 for all). Additionally, the functional MRI parameters and IHC results in patients with breast cancer after NACT also showed a close correlation between D value and CD8a (r = 0.631, P = 0.028). CONCLUSIONS: The treatment response induced by immunogenic chemotherapy could be effectively evaluated using IVIM-DWI. The D values could be potential, sensitive imaging marker for identifying the antitumor immune response initiated by immunogenic chemotherapy. Frontiers Media S.A. 2022-05-13 /pmc/articles/PMC9136146/ /pubmed/35646652 http://dx.doi.org/10.3389/fonc.2022.796936 Text en Copyright © 2022 Hu, Yu, Yin, Du and Cai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Hu, Junjiao
Yu, Xin
Yin, Peidi
Du, Bin
Cai, Xiangran
Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy
title Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy
title_full Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy
title_fullStr Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy
title_full_unstemmed Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy
title_short Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy
title_sort intravoxel incoherent motion diffusion-weighted mr imaging for monitoring the immune response of immunogenic chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136146/
https://www.ncbi.nlm.nih.gov/pubmed/35646652
http://dx.doi.org/10.3389/fonc.2022.796936
work_keys_str_mv AT hujunjiao intravoxelincoherentmotiondiffusionweightedmrimagingformonitoringtheimmuneresponseofimmunogenicchemotherapy
AT yuxin intravoxelincoherentmotiondiffusionweightedmrimagingformonitoringtheimmuneresponseofimmunogenicchemotherapy
AT yinpeidi intravoxelincoherentmotiondiffusionweightedmrimagingformonitoringtheimmuneresponseofimmunogenicchemotherapy
AT dubin intravoxelincoherentmotiondiffusionweightedmrimagingformonitoringtheimmuneresponseofimmunogenicchemotherapy
AT caixiangran intravoxelincoherentmotiondiffusionweightedmrimagingformonitoringtheimmuneresponseofimmunogenicchemotherapy